AEGiS-FDA: FDA approved trimetrexate glucuronate for the treatment of moderate to severe Pneumocystis carinii pneumonia (PCP)

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

FDA approved trimetrexate glucuronate for the treatment of moderate to severe Pneumocystis carinii pneumonia (PCP)

Food and Drug Administration, U.S. Department of Health and Human Services - December 20, 1993
Arthur Whitmore (301) 443-4177

FDA has approved trimetrexate glucuronate for the treatment of moderate to severe Pneumocystis carinii pneumonia (PCP), a potentially fatal infection that often strikes people with AIDS.

Trimetrexate is the first drug approved for severe PCP, although three other drugs are approved for treatment of patients with milder forms of the disease. A substantial number of PCP patients fail to respond to, or are intolerant of, these other drugs -- trimethoprim/sulfamethoxazole, injectable pentamidine and atovaquone.

Trimetrexate must be administered concurrently with leucovorin (folinic acid) to protect against potential toxic effects of tremetrexate in human cells. Patients must be monitored carefully and must continue leucovorin therapy for 72 hours past the last dose of trimetrexate.

The drug was given expanded distribution prior to approval under a "treatment IND" in February 1988 -- the first AIDS-related drug to have been granted this status. Treatment IND regulations provide a mechanism for making promising experimental drugs available to patients with certain serious or life-threatening conditions before all clinical trials required for approval have been completed.

U.S. Bioscience Inc. of West Conshohocken, Pa., manufactures trimetrexate and will market it under the name NeuTrexin.

931220
FD931201

SOURCE: Food and Drug Administration (FDA).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .